195 related articles for article (PubMed ID: 32040834)
1. Increased Levels of Plasma Tumor Necrosis Factor-α Mediate Schizophrenia Symptom Dimensions and Neurocognitive Impairments and Are Inversely Associated with Natural IgM Directed to Malondialdehyde and Paraoxonase 1 Activity.
Maes M; Sirivichayakul S; Matsumoto AK; Maes A; Michelin AP; de Oliveira Semeão L; de Lima Pedrão JV; Moreira EG; Barbosa DS; Geffard M; Carvalho AF; Kanchanatawan B
Mol Neurobiol; 2020 May; 57(5):2333-2345. PubMed ID: 32040834
[TBL] [Abstract][Full Text] [Related]
2. In Schizophrenia, Deficits in Natural IgM Isotype Antibodies Including those Directed to Malondialdehyde and Azelaic Acid Strongly Predict Negative Symptoms, Neurocognitive Impairments, and the Deficit Syndrome.
Maes M; Kanchanatawan B; Sirivichayakul S; Carvalho AF
Mol Neurobiol; 2019 Jul; 56(7):5122-5135. PubMed ID: 30484113
[TBL] [Abstract][Full Text] [Related]
3. Schizophrenia phenomenology comprises a bifactorial general severity and a single-group factor, which are differently associated with neurotoxic immune and immune-regulatory pathways.
Maes M; Vojdani A; Geffard M; Moreira EG; Barbosa DS; Michelin AP; Semeão LO; Sirivichayakul S; Kanchanatawan B
Biomol Concepts; 2019 Nov; 10(1):209-225. PubMed ID: 31734647
[TBL] [Abstract][Full Text] [Related]
4. Lowered Antioxidant Defenses and Increased Oxidative Toxicity Are Hallmarks of Deficit Schizophrenia: a Nomothetic Network Psychiatry Approach.
Maes M; Sirivichayakul S; Matsumoto AK; Michelin AP; de Oliveira Semeão L; de Lima Pedrão JV; Moreira EG; Barbosa DS; Carvalho AF; Solmi M; Kanchanatawan B
Mol Neurobiol; 2020 Nov; 57(11):4578-4597. PubMed ID: 32754898
[TBL] [Abstract][Full Text] [Related]
5. In Schizophrenia, Increased Plasma IgM/IgA Responses to Gut Commensal Bacteria Are Associated with Negative Symptoms, Neurocognitive Impairments, and the Deficit Phenotype.
Maes M; Kanchanatawan B; Sirivichayakul S; Carvalho AF
Neurotox Res; 2019 Apr; 35(3):684-698. PubMed ID: 30552634
[TBL] [Abstract][Full Text] [Related]
6. High Mobility Group Protein 1 and Dickkopf-Related Protein 1 in Schizophrenia and Treatment-Resistant Schizophrenia: Associations With Interleukin-6, Symptom Domains, and Neurocognitive Impairments.
Al-Dujaili AH; Mousa RF; Al-Hakeim HK; Maes M
Schizophr Bull; 2021 Mar; 47(2):530-541. PubMed ID: 32971537
[TBL] [Abstract][Full Text] [Related]
7. Lowered paraoxonase 1 (PON1) activity is associated with increased cytokine levels in drug naïve first episode psychosis.
Brinholi FF; Noto C; Maes M; Bonifácio KL; Brietzke E; Ota VK; Gadelha A; Cordeiro Q; Belangero SI; Bressan RA; Vargas HO; Higachi L; de Farias CC; Moreira EG; Barbosa DS
Schizophr Res; 2015 Aug; 166(1-3):225-30. PubMed ID: 26123170
[TBL] [Abstract][Full Text] [Related]
8. Deficit schizophrenia and its features are associated with PON1 Q192R genotypes and lowered paraoxonase 1 (PON1) enzymatic activity: effects on bacterial translocation.
Matsumoto AK; Maes M; Supasitthumrong T; Maes A; Michelin AP; de Oliveira Semeão L; de Lima Pedrão JV; Moreira EG; Kanchanatawan B; Barbosa DS
CNS Spectr; 2021 Aug; 26(4):406-415. PubMed ID: 32638685
[TBL] [Abstract][Full Text] [Related]
9. Construction of a Neuro-Immune-Cognitive Pathway-Phenotype Underpinning the Phenome of Deficit Schizophrenia.
Al-Hakeim HK; Almulla AF; Al-Dujaili AH; Maes M
Curr Top Med Chem; 2020; 20(9):747-758. PubMed ID: 31994463
[TBL] [Abstract][Full Text] [Related]
10. Towards a new classification of stable phase schizophrenia into major and simple neuro-cognitive psychosis: Results of unsupervised machine learning analysis.
Kanchanatawan B; Sriswasdi S; Thika S; Stoyanov D; Sirivichayakul S; Carvalho AF; Geffard M; Maes M
J Eval Clin Pract; 2018 Aug; 24(4):879-891. PubMed ID: 29790237
[TBL] [Abstract][Full Text] [Related]
11. The Effects of Tryptophan Catabolites on Negative Symptoms and Deficit Schizophrenia are Partly Mediated by Executive Impairments: Results of Partial Least Squares Path Modeling.
Kanchanatawan B; Maes M
CNS Neurol Disord Drug Targets; 2018; 17(6):473-486. PubMed ID: 29968545
[TBL] [Abstract][Full Text] [Related]
12. The Neuroimmune and Neurotoxic Fingerprint of Major Neurocognitive Psychosis or Deficit Schizophrenia: a Supervised Machine Learning Study.
Al-Hakeim HK; Almulla AF; Maes M
Neurotox Res; 2020 Mar; 37(3):753-771. PubMed ID: 31916129
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of interleukin-6 and tumor necrosis factor-alpha in exacerbation and remission phase of schizophrenia.
Dunjic-Kostic B; Jasovic-Gasic M; Ivkovic M; Radonjic NV; Pantovic M; Damjanovic A; Poznanovic ST; Jovanovic A; Nikolic T; Petronijevic ND
Psychiatr Danub; 2013 Mar; 25(1):55-61. PubMed ID: 23470607
[TBL] [Abstract][Full Text] [Related]
14. Breakdown of the Paracellular Tight and Adherens Junctions in the Gut and Blood Brain Barrier and Damage to the Vascular Barrier in Patients with Deficit Schizophrenia.
Maes M; Sirivichayakul S; Kanchanatawan B; Vodjani A
Neurotox Res; 2019 Aug; 36(2):306-322. PubMed ID: 31077000
[TBL] [Abstract][Full Text] [Related]
15. TNF-α and IL-6 are associated with the deficit syndrome and negative symptoms in patients with chronic schizophrenia.
Goldsmith DR; Haroon E; Miller AH; Strauss GP; Buckley PF; Miller BJ
Schizophr Res; 2018 Sep; 199():281-284. PubMed ID: 29499967
[TBL] [Abstract][Full Text] [Related]
16. Chronic fatigue syndrome and fibromyalgia-like symptoms are an integral component of the phenome of schizophrenia: neuro-immune and opioid system correlates.
Mousa RF; Al-Hakeim HK; Alhaideri A; Maes M
Metab Brain Dis; 2021 Jan; 36(1):169-183. PubMed ID: 32965599
[TBL] [Abstract][Full Text] [Related]
17. In schizophrenia, psychomotor retardation is associated with executive and memory impairments, negative and psychotic symptoms, neurotoxic immune products and lower natural IgM to malondialdehyde.
Maes M; Sirivichayakul S; Kanchanatawan B; Carvalho AF
World J Biol Psychiatry; 2020 Jun; 21(5):383-401. PubMed ID: 32031479
[No Abstract] [Full Text] [Related]
18. Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment.
Erbağci AB; Herken H; Köylüoglu O; Yilmaz N; Tarakçioglu M
Mediators Inflamm; 2001 Jun; 10(3):109-15. PubMed ID: 11545247
[TBL] [Abstract][Full Text] [Related]
19. Deficit Schizophrenia Is Characterized by Defects in IgM-Mediated Responses to Tryptophan Catabolites (TRYCATs): a Paradigm Shift Towards Defects in Natural Self-Regulatory Immune Responses Coupled with Mucosa-Derived TRYCAT Pathway Activation.
Kanchanatawan B; Sirivichayakul S; Ruxrungtham K; Carvalho AF; Geffard M; Anderson G; Maes M
Mol Neurobiol; 2018 Mar; 55(3):2214-2226. PubMed ID: 28290151
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory and Oxidative Pathways Are New Drug Targets in Multiple Episode Schizophrenia and Leaky Gut, Klebsiella pneumoniae, and C1q Immune Complexes Are Additional Drug Targets in First Episode Schizophrenia.
Maes M; Vojdani A; Sirivichayakul S; Barbosa DS; Kanchanatawan B
Mol Neurobiol; 2021 Jul; 58(7):3319-3334. PubMed ID: 33675500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
